New drug combo offers hope for Hard-to-Treat transplant complication
Disease control
Recruiting now
This early-phase study tests a combination of two drugs, ruxolitinib and fostamatinib, for people with chronic graft-versus-host disease (cGVHD) that hasn't responded well to steroids. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack the …
Phase: PHASE1 • Sponsor: Stefanie Sarantopoulos, MD, PhD. • Aim: Disease control
Last updated May 05, 2026 11:55 UTC